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Study of the c-Met-HGF axis in non-small cell lung cancer (NSCLC) has focused on
the roles of c-MET signaling in neoplastic epithelial cells and the secretion of its ligand
hepatocyte growth factor (HGF) by tumor stromal cells. However, there is increasing
evidence that some leukocyte sub-sets also express c-MET raising the possibility of an
immunomodulatory role for this axis. Consequently, the role of the c-MET- HGF axis in
immunoncology is an active area of ongoing research. This review summarizes current
knowledge of c-MET expression in NSCLC, the prognostic significance of these findings
and the mechanisms by which the c-MET-HGF axis might act in NSCLC, focusing on the
emerging evidence for an immunoregulatory role.
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INTRODUCTION: NON-IMMUNOLOGICAL ROLES FOR THE
c-MET-HGF AXIS IN NON-SMALL CELL LUNG CANCER
c-MET is a tyrosine kinase receptor with an extracellular α-chain and a transmembrane β-chain
joined by disulphide bonds. In the steady state, the receptor is primarily found on epithelial
cells where it regulates cell motility and proliferation (1). The ligand for c-MET is hepatocyte
growth factor (HGF), which is produced by mesenchymal cells in an inactive form (1). Activation
of HGF requires the action of a serine protease and this occurs in localized in areas of tissue
injury (2). Abnormal c-MET signaling has been demonstrated in a number of human cancers as a
result of c-MET receptor overexpression, receptor mutation or amplification, HGF overexpression
or the formation of abnormal autocrine signaling (3). c-MET activation in cancer promotes;
communication between mesenchymal cells and epithelial cells, tissue infiltration, cancer cell
proliferation, and the induction of angiogenesis (1, 4–6). In addition selective inhibition or
SiRNA knockdown of c-MET decreased the viability of non-small cell lung cancer (NSCLC) cells
demonstrating the direct effects of c-MET in promoting tumor growth (7).
In lung adenocarcinomas various missense mutations and alternatively spliced products have
been identified. These include Exon-14 splice mutations that result in reduced receptor degradation
and prolonged activation of the c-MET receptor, and have been reported to occur in 3% of lung
adenocarcinoma and 2.3% other lung tumors (8). In-vitro studies by Frampton et al., support the
conclusion that Exon-14 splice mutated tumors will respond to anti c-MET therapies. Case reports
from three patients also provides limited clinical data to support this conclusion (8). There are also
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selected reports of clinical responses to c-MET inhibitors in
clinical settings in patients with splice mutations or amplification
of the c-MET receptor (8–11). The frequency with which human
NSCLC tumors express c-MET protein varies between studies,
ranging from 25 to 100% and depends on the method of
measuring c-MET, as well as and the authors’ definition of c-MET
TABLE 1 | Studies assessing c-MET and/or HGF in NSCLC, methods of assessment and correlation with survival.
References Findings Methodology for c-MET or HGF
assessment
Association with survival
Ichimura et al. (12) c-MET protein identified in 54% of patients
with NSCLC
77% positive in LUAD and 37% positive
in LUSC
Immunohistochemistry and western blotting for
c-MET receptor in 104 surgical samples
4 year survival times were poorer for
adenocarcinoma patients with strong
c-met expression in western blot samples
compared to patients with c-MET negative
adenocarcinomas (P < 0.01)
Nakamura et al. (13) 74.6% of adenocarcinomas c-Met positive
High expression in 36.1% and
phospho-c-Met staining seen in 21.5%. HGF
at high levels found in 31.5%
Immunohistochemistry for c-MET, phospho c-MET,
and HGF on 130 resected patient lung
adenocarcinomas
No relationship seen between MET
expression and survival. However, high
c-MET expression was associated with
metastasis to lymph nodes and advanced
pathological stage
Dziadziuszko et al. (14) 25% of samples were c-MET positive using
the MetAb scoring system
Immunohistochemistry and/or in situ hybridization
for MET Gene copy numbers in 189 patients.
Assessment of immunohistochemistry samples with
two scoring systems. The MetMAb trial scoring
system (>50% of cell with moderate or strong
staining) and with a hybrid scoring ranging from 0
to 400
No relationship between c-MET protein
expression or MET copy number and
overall survival was detected
Ma et al. (7) 100% c-MET positive with 61% of NSCLC
demonstrating strong c-MET expression
(67% LUAD, 57% LUSQ, and 57% large cell
strongly positive)
Gene overexpression was present in lung
adenocarcinoma (adjusted p 0.0007) and
lung carcinoids (adjusted p 0.013). There was
no significant difference between gene
expression from normal tissues and
squamous carcinomas samples
(adjusted p >1)
Immunohistochemistry in 32 samples for total
c-MET and phospho c-MET. Staining was graded
as absent (0), weak (+1), or strong (+2)
Survival data not reported in this study
Siegfried et al. (15) HGF levels not different between patients
with stage 1 tumors compared to stage 2 or
3. Higher median and mean concentrations
were present in patients where disease
reoccurrence was recorded during the follow
up period (p 0.001)
Quantitative western blot in 56 resected NSCLC
samples
Patients with HGF concentrations greater
than the median had poorer overall survival
(p < 0.03). Multivariate cox analysis
showed that HGF was an independent
prognostic indicator (p 0.0001)
Hosoda et al. (16) High HGF concentrations were present in
32% of patients. No difference in c-Met
overexpression in patients in the high and low
HGF groups (p 0.91)
c-MET expression assessed using
immunohistochemistry and c-MET overexpression
defined as >50% staining, 10–49% as “middle
degree” expression, 1–10% as “minimal” expression
and <1% as negative. Whole blood HGF
concentrations were measured using an ELSIA
quantitative sandwich immunoassay in 25 patients.
Patient were divided in to groups with high
(>7.2 ng/ml) and low HGF concentrations
Patients with concentrations of HGF >
7.2 ng/ml had a 5 year survival rate of 50%
compared to 87.8% of patients in the HGF
low HGF (p 0.015)
Tsuji et al. (17) Serum HGF concentrations were raised in
patients compared to healthy controls prior to
treatment (p 0.01)
81 patients with NSCLC with serum HGF levels
measured by ELISA. Time points assessed: at
pre-treatment, 1–2 months after starting treatment,
when best treatment response was recoded and
when disease progression occurred
There was a significant association
between poor PFS and positive serum
HGF 1–2 months after starting treatment p
< 0.01. In patients with adenocarcinoma
treated with second line chemotherapy,
high HGF pre-treatment 1–2 months after
treatment was associated with poor PFS
(p < 0.01)
LUAD, lung adenocarcinoma; LUSC, lung squamous-cell carcinoma; PFS, progression free survival; HGF, hepatocyte growth factor.
positivity (Table 1). The association between tumor production
of HGF and NSCLC survival is also summarized (Table 1).
These observational studies are limited in their conclusions
due to their retrospective nature and it is difficult to directly
compare the different methodologies used, however, these studies
highlight that there may be a trend toward increased c-MET
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expression or HGF production with poor patients outcomes.
The importance of protein expression and gene amplification
has been questioned, as clinical studies using c-MET targeting
therapies recruiting patients with protein overexpression or gene
amplification have produced disappointing results. This is well-
reviewed by Hughes and Siemann (18), although early reports
from a phase 1 clinical study of 40 patients [NCT00585195]
suggest patients with highMET amplificationmay respond better
to treatment with crizotinib (19). Identifying c-MET pathway
activation may be a more appropriate selection criteria (18).
With emerging evidence that c-MET may play a role in anti-
cancer immune responses, understanding how c-METmay affect
immunotherapy is another potential area to explore to see if these
therapies could be used to greater effect.
c-MET and Immune Evasion
The ability to evade anti-tumor immune responses is a hallmark
of cancer (20), however the discovery that checkpoint inhibition
can overcome immunosuppression has established the anti-
cancer potential of adaptive immune responses and ushered
in the age of cancer immunotherapy (21). There is evidence
that c-MET expression may be associated with expression of
immunoregulatory molecules such as programmed cell death
ligand (PD-L1) and Indoleamine-2,3-dixoygenase (IDO) in
cancer cells. As a result, c-MET presents an attractive therapeutic
target as there are clinically available inhibitors which may
modulate the ability of cancer cells to evade anti-tumor immune
responses. Programmed death 1 (PD-1) is a co-inhibitory
molecule expressed on activated T-cells in response to antigenic
stimulation. When the activating antigen is cleared PD-1 is
down regulated, however where the antigen persists such as
in cancer, PD-1 remains highly expressed on T-cells (22). As
a means of preventing excessive immune response in the face
of chronic antigen stimulation T-cell activity can be suppressed
by binding of PD-1 to ligands on dendritic cells, B-cells and
macrophage and cancer cells such as PD-L1 which are increased
by inflammation or by some cancer mutations (22). PD-L1
binding with PD-1 on activated T-lymphocytes inhibits T-
cell proliferation and cytokine release (22–24), thus inhibiting
anti-tumor immune responses. PD-L1 expression occurs more
frequently with MET activation in NSCLC (25), suggesting
that besides its well-characterized direct anti-tumor effects
inhibition of c-MET signaling may act indirectly to alleviate
immunosuppression. Increasing PD-L1 expression correlated
positively with MET gene amplification in 389 NSCLC samples
(26). A separate study of 155 resected NSCLC tumor samples
found MET activation was associated with PD-L1 expression
and demonstrated that in NSCLC cell lines c-MET signaling
directly induces PD-L1 expression (25). Aberrant c-MET activity
can contribute to acquired tumor cell resistance to treatment
with epidermal growth factor receptor (EGFR) targeting tyrosine
kinases (TKIs) such as erlotinib (27, 28). This also includes
the more recently available, third generation TKI osimertinib
(29–31). There is some pre-clinical and clinical evidence that
treating patients resistant to EGFR TKIs with c-MET inhibitors
may improve outcomes. Treating erlotinib resistant cells with
the c-MET inhibitor crizotinib decreased PD-L1 protein and
gene expression, demonstrating a positive association between c-
MET signaling and PD-L1 expression (32). Clinical reports also
document responses to crizotinib in patients with osimertinib
resistance (10). In addition, a marked response to a combination
of erlotinib and crizotinib given concurrently in a patient with
primary erlotinib resistance has also been reported (9). However,
it is unknown from patient reports if crizotinib had any effect on
PD-L1 expression. The results from Demuth et al. suggest that
the c-MET axis may cause resistance to EGFR tyrosine kinases
and increase the ability of the tumor to evade immune responses.
If a relationship between c-MET inhibitors and PD-L1 expression
is found in patient samples, then this could suggest that addition
of c-MET inhibitors could also affect tumor immunity. This
may be important in tumors with MET exon 14 alternations as
they response more poorly to immune check point inhibitors.
However, in a study where tumor samples with MET exon
14-alterations were available for assessment of PD-L1 status,
outcomes with PD-1 blockade were poorer than for unselected
patients (33). The authors also found treatment outcomes were
not better in tumors with higher PD-L1 expression. The impact
of the c-MET axis on PD-L1 related outcomes may relate to the
type of abnormal c-MET activity present. c-MET may also affect
inflammation induced PD-L1 expression.
IFN-γ induced upregulation of PD-L1 expression represents
a negative control mechanism to limit the magnitude of T-cell
responses (34, 35) and this pathway may also be modulated
by c-MET inhibition. In response to IFN-γ produced by anti-
tumor T-cells re-invigorated by checkpoint immunotherapy,
increased tumor cell expression of PD-L1 can further raise the
threshold for effective anti-tumor immunity (36). Although c-
MET activation induces PD-L1 expression via a pathway distinct
to that used by IFN-γ and independent of JAK/ STAT activation
(25), inhibition of c-MET signaling blocks PD-L1 upregulation
in response to both HGF and IFN-γ (25, 37). By blocking the
capacity of IFN-γ to elevate PD-L1 expression c-MET inhibition
may act as an effective co-treatment to increase the effectiveness
of immune checkpoint blockade in patients with tumors with
aberrant MET activity.
Production of Indoleamine-2,3-dixoygenase (IDO) by tumor
cells is another pathway by which the c-MET-HGF axis may
contribute to an immunosuppressive tumor microenvironment
(38). IDO exerts immunosuppressive effects on T-cells and
natural killer cells (NK cells) via regulation of kynurenic
pathways and production of metabolites which deplete the
extracellular environment of tryptophan required for T-cell
function (39). Wang et al. performed experiments using the IDO
expressing ovarian cancer cell line SKOV-3. Pharmacological
inhibition of the c-MET receptor decreased IDO expression in
a concentration dependent fashion. Additionally, when SKOV-3
cells were transfected to express the HGF variant NK4, which is
a competitive antagonist for the c-MET receptor, IDO expression
was inhibited. The variants expressing NK4 and therefore lacking
IDO were more susceptible to the cytotoxic effects of NK cells
suggesting that c-MET can indirectly influence NK effects on
tumor cells. Murine experiments demonstrated that tumors
expressing NK4 recruited more NK cells into the tumor stroma
in-vivo and had reduced growth compared to tumors in the
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control group (38). Further work is required to see if increased
IDO expression and therefore the function of NK or T-cells can
be linked to c-MET expression in NSCLC cells.
The evidence above, indicates that role of aberrant c-
MET activity on expression of immunoregulatory molecules by
tumor cells is worthy of further investigation in both MET
dependent and non-MET dependent NSCLC as is the potential
combination of c-MET targeting therapies with immune check
point inhibitors.
Leukocytes and c-MET Expression
The expression of c-MET is not limited to epithelial cells.
The HGF-c-MET axis is involved in the binding, propagation,
and survival of hematopoietic progenitor cells (40) and there
is an emerging body of evidence that c-MET is expressed by
mature leukocytes in murine and human tissues. The role of c-
MET expressing leukocytes in inflammatory, autoimmune, and
neoplastic disease is of increasing interest, although the role of
these cells in human disease is still incompletely understood.
The effect of c-MET on tumor associated leukocytes and cancer
outcomes is worthy of further exploration as it may be possible
to target leukocytes with c-MET inhibitors. Potential effects of
the c-MET-HGF axis on leukocyte functions are summarized in
Figure 1.
Neutrophils are best understood for their role within the
innate immune system, serving as short lived, phagocytic
cells acting against pathogens such as bacteria (41). There
is an increasing appreciation of the immunomodulatory
role of neutrophils in shaping adaptive immune responses
including anti-tumor immunity. The tumor microenvironment
influences the phenotype and function of tumor-associated
neutrophils (TANs) which can exert both pro- and anti-
tumor effects. This has been reviewed elsewhere (42–44). The
importance of better understanding the role of neutrophils
in lung cancer is clear as they can comprise a significant
proportion of the cellular tumor mass, making up between 5
and 25% of the infiltrating leukocytes (45, 46). Importantly
neutrophil depletion studies in mice have demonstrated
that neutrophils can limit the effectiveness of anti-PD-1
immunotherapy (47). This indicates factors influencing the
recruitment and function of neutrophils within the tumor
microenvironment may impact the efficacy of checkpoint
inhibition (47). Given the use of PD-1 targeting therapies
in NSCLC this may be important in the treatment of lung
cancer patients. Evidence that c-MET targeting drugs may
effect TAN functions and checkpoint inhibition efficacy is
summarized below.
Sub-populations of murine and human neutrophils
stimulated by inflammatory stimuli express c-MET (48).
c-MET is required for the egress of neutrophils from the bone
marrow and transendothelial migration of neutrophils into
tissues in murine models of cancer (48, 49). c-MET silencing
in neutrophils resulted in increased tumor growth in mice,
demonstrating c-MET positive neutrophils have anti-tumor
properties (48). Furthermore, in-vitro experiments showed c-
MET knock out neutrophils have reduced nitric oxide-mediated
cytotoxicity against neoplastic cells, whereas c-MET positive,
HGF-stimulated neutrophils demonstrated increased nitric oxide
FIGURE 1 | Proposed functions of c-MET/HGF axis in tumor associated leukocyte function. All images were sourced and modified from Servier Medical Art, licensed
under a Creative Common Attribution 3.0 Generic License. http://smart.servier.com//.
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(NO) release and enhanced cytotoxicity (48). TNF-α produced
by tumor cells induced c-MET expression in neutrophils via
activation of NF-kB (48), further illustrating how the prevailing
cytokine milieu can ignite anti-tumor effector functions in
neutrophils. However, besides its beneficial role in tumor
cell killing, TAN production of NO may also suppress T-cell
responses and limit the effectiveness of immunotherapy. In a
murine melanoma model, adoptive T-cell transfer induced the
recruitment of immunosuppressive c-MET positive neutrophils
to the tumor and tumor draining lymph nodes (49). These
TANs displayed increased expression of immunosuppressive
genes including PD-L1, ARG1, and iNOS. The majority of
TANs expressed PD-L1 and neutrophils from within the tumor
and tumor-draining lymph nodes expressed higher levels of
c-MET than those found in the spleen (49). Administering
c-MET inhibitors alongside adoptive T-cell therapy prevented
neutrophil recruitment, improved tumor eradication and
increased survival in mouse tumor models (49). Cell-specific
knockdown of c-MET expression in neutrophils also enhanced
the effectiveness of adoptive T-cell therapy, reducing recruitment
of reactive neutrophils and increasing survival of tumor reactive
T-cells (49). The different pro and anti-tumor effects of c-Met
expressing neutrophils reported in the Glodde and Finisguerra
studies may be explained by differences in the inflammatory
milieu of the tumor microenvironment. Following either
adoptive T -cell therapy or checkpoint inhibition enhanced
T-cell responses result in increased IFN-γ production which may
promote suppressive effects. PD-L1 expression is readily induced
in neutrophils in response to IFN-γ produced by activated T-cells
(49). Thus, cytokines produced by both tumor cells [TNF-α
promoting c-MET expression (50) and tumor reactive T-cells (via
IFN-γ induced PD-L1 expression) (49)] co-operate in driving
the recruitment and immunosuppressive phenotype of TANs.
Limiting pro-tumor neutrophil mediated T-cell suppression may
come at the expense of direct NO-mediated neutrophil killing
of tumor cells. Therefore, whether there are anti-cancer benefits
to inhibiting the c-MET dependent recruitment of TANs likely
depends on the magnitude of the adaptive anti-tumor response.
In the presence of a strong anti-tumor immune response or
when used as an adjunct to checkpoint blockade or adoptive
T-cell therapy, cytotoxic T-cells are likely to be the most efficient
anti-tumor effector cells. However, as Glodde et al., where able to
demonstrate a positive effect of c-MET silencing and inhibitors in
mice with and without c-MET dependent tumors, the possibility
of using c-MET inhibitors to improve checkpoint inhibitor
associated outcomes in patients is worthy of investigation.
The role of TANs in c-MET associated patient outcomes has
been investigated in treatment naive patients with hepatocellular
carcinoma (HCC) (51). Although, tumor cell c-MET expression
when considered alone was not predictive of outcome, MET
expression by HCC cells was inversely associated with overall
survival and disease free progression times in the subgroup of
patients within this cohort with large numbers of neutrophils
at the invading tumor margins (51) Further in-vitro work by
this group, determined that exposing neutrophils to culture
supernatants fromHCC cell lines or primary HCC cells increased
production of HGF by neutrophils. GM-CSF was found to be
increased in culture supernatants from HCC cells and treatment
of neutrophils with recombinant GM-CSF lead to increase in
HGF, indicating GM-CSF is important in regulating neutrophil
production of HGF. The possible pro-tumor effects of these
HGF secreting neutrophils was also investigated. Conditioned
media from HGF producing TANs promoted hepatoma cell
migration, whereas the media from blood derived neutrophils,
which produce less HGF did not. In addition, treatment of TANs
with c-MET inhibitors reduced TAN associated hepatoma cell
migration (51).
The studies by He et al., Finisguerra et al., and Glodde et al.,
suggest c-MET inhibition could become an adjunct therapy
to established immunotherapies because they demonstrate a
role for c-MET in the recruitment of TANs, show that tumor
derived GM-CSF can stimulate increased HGF-production by
neutrophils and that HGF can promote increased expression
of PD-L1 and PD-L2 on neutrophils. Further work is needed
to see if this could be applicable to the treatment of NSCLC.
Currently, few studies have investigated expression of c-MET
on TANs from human NSCLC. In four NSCLC patients, where
neutrophils were isolated from tumor samples and from non-
cancerous lung tissue, gene expression of MET in TANs was
greater than in neutrophils from healthy tissues (48). However, in
this study there was no assessment of c-MET protein expression
or activation. Immunohistochemistry for HGF and the c-MET
receptor has been investigated in eight patient bronchioaveolar
lavage (BAL) samples and five paired tumor and adjacent
non-tumor tissue samples from patients with bronchioaveloar
carcinoma (BAC) (52). The c-MET receptor was absent on
polymorphonuclear cells suggesting c-MET positive neutrophils
are uncommon in BAC. Neutrophils were however a major
source of HGF; HGF levels in the BAL fluid correlated with
absolute BAL neutrophil counts and increasing BAL HGF
concentrations were associated with shorter survival time. BAC,
now termed adenocarcinoma spectrum disease, is often a more
indolent cancer with a more favorable prognosis. Therefore, care
should be taken when applying the results of this study to other
types of NCSLC many of which will behave more aggressively.
Lymphocytes play a vital role in influencing immune
responses to tumors. Whether lymphocytes mount an immune
response or a promote immune tolerance toward tumor cells is
influenced by a number of factors including, cytokines, tumor cell
immunoregulatory molecules, and secreted proteins, as reviewed
by Chraa et al. (53). In addition many recent advancements in
NSCLC therapy act to alter T-cell responses. Although to our
knowledge c-MET expressing lymphocytes have not be found
in human NSCLC cancer there is evidence that subsets of
lymphocytes may response to HGF in other types of human
cancer. Therefore, if c-MET may have a direct effect on T-
cells, potentially augmenting immunotherapy this could provide
alternative uses for c-MET inhibitors in both MET dependent
and non-MET dependent tumors.
Hepatocyte growth factor can attenuate CD8 positive
responses in mice due to effects on antigen presenting cells
(APCs)/generating tolerogenic dendritic cells (54, 55). c-Met
expression has been identified in human melanoma samples (56)
and a small percentage ofmurine cytotoxic T-cells express c-MET
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receptors in response to activation (56). c-MET positive CD8
positive T-cells are more cytotoxic than c-MET negative CD8
positive T-cells when assessed in vivo and in vitro (56). c-MET
positive cytolytic T-cells expressed higher levels of granzyme
B and perforin and showed a trend toward producing higher
concentrations of IFN-γ and TNF-α. However, when these cells
were exposed to HGF in vivo, cytolytic effects and cytokine
production were reduced. This suggests HGF acts to restrain
immune responses (56). c-MET inhibition may however, also
act directly upon T-cells to enhance effector functions. The
hypothesis is supported by experiments that indicate c-MET
positive CD8 positive cells have increased ability to reduce
melanoma pulmonary metastasis compared to c-MET negative
CD8 positive cells, which can be abrogated by the addition of
HGF (56). c-MET positive CD8 positive lymphocytes have been
identified in human tumors; biopsy samples from fourmelanoma
patients showed 8–35% of CD8 positive T-lymphocytes in
close proximity to melanoma cells expressed c-MET (56). The
prevalence of c-MET positive T-cells in other cancers, their
functional capacities and the consequences of c-MET inhibition
on T-cell function requires ongoing research.
c-MET positive B-lymphocytes in solid tumors have not, to
the authors knowledge been reported. However, the HGF/c-Met
axis has been shown to play a role in survival of mature murine
B lymphocytes via the CD74 pathway (57), and is a paracrine
factor involved with regulating B cell adhesion in lymphoid
tissue (58, 59). High MET mRNA number has been associated
with poor outcomes in patients with multiple myeloma (60).
Additionally protein expression for c-MET has been found on
the plasma cells of 40% of patients with multiple myeloma, but
is absent in healthy donors (61). MET expression is documented
in 30% of diffuse large B-cell lymphomas in one study (62)
and is increased in 73.2% of patients in another study (63).
Targeting c-MET has been suggested as a possible therapeutic
option for this disease (63). Despite B lymphocytes being present
at very low frequencies in NSCLC (46), tumor infiltrating B-
lymphocytes have an important impact on CD4+ cells behavior
and phenotype (64, 65). Therefore, the possibility that B-cells
may express c-MET in the NSCLC microenvironment requires
further investigation.
Lymphocyte responses can be influenced by other types of
leukocytes such as dendritic cells. As there is some evidence of
c-MET expressing dendritic cells targeting these cells may also
provide another avenue via which c-MET inhibitors would be
used to improve immunotherapy outcomes in cancer patients.
Dendritic cells (DCs) are the primary antigen presenting
cell population responsible for initiating T-cell activation and
development of adaptive immune-responses. c-Met expression
in dendritic cells has been best studied in inflammatory disease
wherein it drives a tolerogenic rather than immunogenic
phenotype. In a model of allergic asthma messenger RNA
(mRNA) for c-MET was identified in murine DC cells and HGF
suppressed the capability of DC to present antigens (66). HGF has
also been shown to promote the development of tolerogenic DCs
in experimental autoimmune encephalomyelitis (54). Besides the
role of c-MET in promoting immunotolerance, Met-deficient
skin DCs failed to migrate to skin draining lymph nodes
following activation, resulting in reduced contact hypersensitivity
responses (67). These results suggest that c-MET acts on DCs
altering adaptive immune responses. Investigating the possible
role of the c-MET-HGF axis in the regulation of anti-tumor
immune responses is therefore an area worthy of investigation.
Monocytes are circulating precursors to macrophages and
dendritic cells, which can have immunomodulatory effects
on local T-cell responses (68). c-Met has been found on
CD14 positive human monocytes during differentiation and
in response to inflammatory cytokines such as lL-6, TNF-α,
IFN-γ, IL-1B, and endotoxin (69–71). Activation of monocytes
increases secretion of HGF and expression of the enzyme
urokinase-type plasminogen activator (uPA) needed to convert
pro-HGF to its active form, thus increasing both availability
and bioactivity of HGF (70). In addition, HGF increases
the transcription of cytokines including IL-6, GM-CSF and
G-CSF (70). In contrast Chen et al. found HGF treated
monocytes displayed an immunosuppressive phenotype and
limited T-cell proliferation in an IL-10 dependent fashion
(71). Similarly Rutella et al. found HGF-treated monocytes
produced increased amounts of immunosuppressive IL-10 and
lower levels of the immunostimulatory cytokine IL-12 p70
(72). Compared to GM-CSF/IL-4 matured monocytes, HGF
treated cells were inefficient in driving T-cell proliferation and
promoted expansion of suppressive Foxp3 positive regulatory
T-cells (72). Gene profiling of HGF stimulated monocytes
showed an increase in transcription of genes associated with
immunotolerance and tumor progression such as IDO, compared
to monocytes stimulated by GM-CSF and IL-4. Co-culturing
CD4 positive T-cells and HGF stimulated monocytes with
an IDO inhibitor partially reversed the hyporesponsiveness of
CD4 positive cells to HGF exposed monocytes. This suggest
that HGF may in part exert some immunosuppressive effects
by affecting IDO expression. As discussed earlier in this
review, the c-MET-HGF pathway has also been implicated
in altered IDO expression by tumor cells (38). These studies
suggest that HGF/c-MET axis may have indirect suppressive
effects on T-cells as a consequence of altering the phenotype
of antigen presenting cells favoring tolerogenic rather than
immunogenic responses.
Myeloid derived suppressor cells (MDSCs) are a group
of leukocytes which act to suppress T-cell effector functions
and can be broadly divided into two populations myeloid
(M-MDSCs) and polymorphonuclear (PMN-MDSCs) (73). M-
MDSCs differ phenotypically from monocytes as they express
no or very little of the T-cell ligand HLA-DR and can be
recognized as CD11b+, HLA-DR−, CD14+CD15− cells (73).
PMN-MDSCs can be classed as CD11b+CD15+CD14−/dim,
HLA-DR− cells but are difficult to differentiate from neutrophils
(73). Use of these markers as a standard to describe MDSCs
has only recently been proposed and therefore literature which
describe MDSCS as having a different phenotype are included in
this review.
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In human blood, CD14 negative leukocytes including MDSCs
(CD14−, CD11b+ CD33+) can constitutively express low levels
of c-Met (74). Culturing peripheral leukocytes withmesenchymal
stem cells (MSCs) or HGF causes an increase in MDSCs. HGF-
expanded MDSCs suppress allogeneic lymphocyte proliferation
and expressed increased immunosuppressive/cytotoxic enzymes
including iNOS and ARG-1 compared to at baseline (74). In
addition the MDSCs cells were able to induce T-regs from
stimulated peripheral blood leukocytes and the ability of MSCs
to expand MDSCs populations was inhibited when c-MET was
pharmacologically blocked or if HGF production was silenced
in cells (74). This suggests that c-MET may be important in
regulation of immunoregulatory processes. Indeed, an abstract
from a pre-clinical study of a c-MET targeting therapeutic
antibody ARGX-111 indicates that the drug can diminish c-MET
positive MDSCs, suggesting a role of this drug in treating c-MET
positive tumors and altering c-MET activity of cells in the tumor
microenvironment (75).
Overall, there is currently little evidence that c-MET
expressing leukocyte subsets exist in NSCLC tumors. However,
evidence that the c-MET/HGF axis can influence leukocyte
activity in the studies discussed above indicates that c-MET
inhibitors may potentially be of benefit via their effects on
immune cells. This raises the possibility that c-MET inhibitors
could be used in patients with non-MET dependent tumors as
well as those with tumor cells with aberrant activity.
TRIALS AND INVESTIGATIONS OF c-MET
TARGETING THERAPIES AND
IMMUNOTHERAPY IN MET DEPENDENT
AND NON-DEPENDENT TUMORS
The potential for c-MET to influence both immunoregulatory
molecules in MET dependent cancers and leukocytes in
either MET dependent or MET independent cancer raises
the possibility that treatments targeting the c-MET axis could
impact on the outcomes of anti-cancer immunotherapies.
Current evidence suggest that immune check point inhibitors
are less effective in tumors with driver mutations including
c-MET (76). The conclusions of a report based on the
IMMUNOTARGET registry, suggests where driver mutations
are found, targeted therapies such as Tyrosine Kinase Inhibitors
should be used before contemplating immunotherapy (76).
However, a significant amount of pre-clinical investigation is
required before this can be considered and this staged approach
does not address the potential for concurrent therapy. The
possibility of drug toxicity must also be considered. A clinical
studying using crizotinib (prescribed for its effects on ALK rather
than c-MET in this incidence), in patients given the PD1- PD-
L1 targeting treatment nivolumab resulted in serious hepatic
toxicity leading to the end of patient enrollment (77). Drugs
and immunotherapies targeting c-MET have been developed for
use in people. Early stage human trials using T-cells modified to
identify the c-MET and PD-L1 proteins (CAR T-Cells) for the
treatment of primary hepatocellular carcinoma are planned (78).
The aim of this trial is to determine the efficacy of this therapy
in increasing overall survival. The potential for these therapies to
alter the immune cell populations as well as targeting neoplastic
cells expressing c-MET and PD-L1 could be interesting in light
of research suggesting c-MET has immunomodulatory functions.
This may allow dual targeting of the c-MET and PD-L1 pathways
without risking the toxicities seen when crizotinib was given to
patients receiving immunotherapy (77).
The c-MET inhibitor crizotinib has been studied as a means
of improving treatment outcomes, via an off target effect.
Responses to some chemotherapy agents is partly due to
causing “immunogenic cell death” which allows immune cells
to be attracted to dying cancer cells and progression free and
overall survival have been linked to the expression of receptors
associated with immunogenic cell death. Crizotinib has been used
to induce immunogenic cell death in a human NSCLC cell line
(79). When cells treated with the chemotherapeutic agents and
crizotinib were injected into mice more mice remained tumor
free after 60 days than mice injected with tumor cells treated
with chemotherapy alone. The in-vitro and in-vivo results suggest
the c-MET inhibitor crizotinib increases immunogenic cell death
and thus improves treatment outcomes. Additionally, these
effects are related to T-lymphocyte infiltration and depletion
of T-cells or blockade of IFN-γ abolishes these effects. As
crizotinib effects appeared to be off target this again suggests
a potential use of c-MET inhibitors in MET dependent and
non-dependent tumors.
SUMMARY
Although, the role of the HGF/c-MET axis as a regulator of
immune function is incompletely understood it is emerging as
a powerful influence in many aspects of immunity. The studies
described above have illustrated its effects on first line responders
such as neutrophils, in directing the migration and stimulatory
capacity of dendritic cells and monocytes through to directly
influencing the function of effector T-cells. These effects occur
in concert with, and must be considered alongside, direct effects
on tumor cells and stromal cells in the tumor microenvironment.
As many novel anti-cancer therapies target immunoregulatory
molecules or the c-MET receptor itself understanding the
relationship between c-MET and immunological responses to
tumors is critical in ensuring these drugs are used to their full
potential benefit.
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